<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311817</url>
  </required_header>
  <id_info>
    <org_study_id>2008P-0002296</org_study_id>
    <nct_id>NCT01311817</nct_id>
  </id_info>
  <brief_title>Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine</brief_title>
  <official_title>Transcutaneous Immunization With actA/plcB-Deleted Listeria Monocytogenes Expressing Influenza A Nucleoprotein (BMB72) and Cholera Toxin Adjuvant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a pilot safety and immunogenicity study of transcutaneous vaccination with&#xD;
      live attenuated Listeria monocytogenes BMB72 bacteria (actA/plcB-deleted, expressing&#xD;
      influenza A nucleoprotein) and a cutaneous adjuvant, native purified cholera toxin.&#xD;
      Transcutaneous vaccination is needle-less application of materials directly to the skin.&#xD;
      Healthy adult volunteers (4 per group) will receive either:&#xD;
&#xD;
        -  Saline (placebo)&#xD;
&#xD;
        -  Cholera toxin adjuvant alone&#xD;
&#xD;
        -  L. monocytogenes BMB72 bacteria alone&#xD;
&#xD;
        -  L. monocytogenes BMB72 bacteria plus Cholera toxin adjuvant&#xD;
&#xD;
      Vaccine solutions will be applied to the upper deltoid area under a standard Tegaderm&#xD;
      dressing. Key primary endpoints include: safety as measured primarily by clinical findings&#xD;
      (VS, cutaneous exams, and systemic reactions), and immune responses as measured by&#xD;
      serological responses to L. monocytogenes, influenza A nucleoprotein, CT, and IFN gamma&#xD;
      ELISPOT responses to listeriolysin and nucleoprotein peptides. Local skin immune responses&#xD;
      will be evaluated by skin biopsy in subjects who agree to that (optional). The study will&#xD;
      begin with 2 &quot;roll-in&quot; subjects receiving both L. monocytogenes and CT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Safety</measure>
    <time_frame>1 year +/-</time_frame>
    <description>Safety is measured primarily by clinical findings (VS, cutaneous exams, and systemic reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>1 year +/-</time_frame>
    <description>Immune responses are measured by serological responses to L. monocytogenes, influenza A nucleoprotein, cholera toxin, and IFN gamma ELISPOT responses to listeriolysin and nucleoprotein peptides.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Saline Patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1mL saline applied to the vaccine patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacteria plus CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.95mL bacterial vector plus 0.05mL cholera toxin</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)</intervention_name>
    <description>1mL liquid contained in an adhesive skin patch</description>
    <arm_group_label>Bacteria plus CT</arm_group_label>
    <arm_group_label>Saline Patch</arm_group_label>
    <other_name>Lot ELH072910</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult 18-55 years old, male or female.&#xD;
&#xD;
          -  Adequate venous access by inspection for frequent blood draws.&#xD;
&#xD;
          -  Must have normal physical exam and laboratory values within the normal range for&#xD;
             age/gender in screening studies (see details below).&#xD;
&#xD;
          -  Be willing to return for 3 vaccinations, and the needed follow-up visits.&#xD;
&#xD;
          -  Not pregnant (WOCBP have pregnancy testing prior to vaccination, on a standard&#xD;
             schedule over the course of the study, and must use contraception).&#xD;
&#xD;
          -  Non-smokers (altered immunity).&#xD;
&#xD;
          -  Body mass index (BMI) less than or equal to 32.5 (the obese have impaired responses to&#xD;
             some vaccines).&#xD;
&#xD;
          -  Normal skin exam.&#xD;
&#xD;
          -  Volunteers must be feeling well and be afebrile (T&lt;99.5) at the time of vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to any penicillin (including penicillin G, penicillin V,&#xD;
             ampicillin, amoxicillin) or sulfa drugs (trimethoprim/sulfamethoxazole is the second&#xD;
             line agent for therapy of listeriosis).&#xD;
&#xD;
          -  Any chronic medical illness or problem requiring chronic medical care. Exceptions:&#xD;
&#xD;
               -  Subjects on one antihypertensive prescribed for essential hypertension, with&#xD;
                  seated BP in the normal range at screening will be accepted. These are&#xD;
                  immunologically normal adults and we do not believe treated essential&#xD;
                  hypertension as a single illness puts these individuals at any greater risk than&#xD;
                  other healthy adults.&#xD;
&#xD;
               -  Subjects using only PRN beta agonists for mild asthma, or cold or&#xD;
                  exercise-induced bronchospams, will be allowed (those with any prior or current&#xD;
                  inhaled or systemic steroids for asthma are excluded).&#xD;
&#xD;
          -  Any chronic or current skin disorder, e.g. eczema, dermatitis, psoriasis, rosacea, or&#xD;
             acne. Prescription medications more than 5 years ago for teenage acne without current&#xD;
             acne on exam or current use of those medications does not exclude subjects.&#xD;
&#xD;
          -  Any acute skin break or problem at the planned vaccination site (deltoid).&#xD;
&#xD;
          -  Upper extremity lymphedema, deformity (e.g. large burn or poorly-healed fracture),&#xD;
             swelling or vascular abnormality on exam. A history of a distant isolated arm, wrist&#xD;
             or hand fracture (more than 5 years earlier) with no residual functional deficit or&#xD;
             visible deformity will not exclude a subject.&#xD;
&#xD;
          -  History of allergy to medical bandages, tape, or adhesives (a Tegaderm patch is used&#xD;
             for application.)&#xD;
&#xD;
          -  No history of bleeding disorder, or anticoagulant medications. (The protocol has an&#xD;
             optional skin biopsy).&#xD;
&#xD;
          -  Pregnancy, attempting pregnancy, or unwillingness to use medically acceptable&#xD;
             contraception for entire study period if sexually active. Women of childbearing&#xD;
             potential will have serum pregnancy testing. Women who are menopausal (over 50 years&#xD;
             of age with no menses for more than one year) or surgically sterilized are not&#xD;
             considered of child-bearing potential and will not require pregnancy testing or&#xD;
             contraception. Acceptable contraception includes: condoms/spermicide, prescription&#xD;
             hormonal contraceptive pills, patches, rings, and implants; IUDs.&#xD;
&#xD;
          -  Any type of chronic prescription medication use for any reason, including acne or skin&#xD;
             conditions. Exceptions: oral contraceptives, depo contraceptives, patch&#xD;
             contraceptives, one antihypertensive agent is allowed, if BP is normal on exam as&#xD;
             noted above.&#xD;
&#xD;
          -  History of keloid scars, or poor wound healing.&#xD;
&#xD;
          -  Previous splenectomy or abdominal procedure where splenectomy was possibly performed -&#xD;
             e.g. laparotomy for trauma. (Not a known risk factor for listeriosis, but might&#xD;
             conceivably result in more serious illness, or alter immune responses to a bacterial&#xD;
             pathogen).&#xD;
&#xD;
          -  Any biomedical implants: cranial plates, joint prostheses, bone screws, pacemakers,&#xD;
             CNS clips, and heart valves. (Exceptions: K wires or 3 or fewer dental implants more&#xD;
             than 2 years post implantation in an otherwise healthy individual with no functional&#xD;
             deficit or deformity will not exclude an individual.)&#xD;
&#xD;
          -  Mitral valve click or prolapse or heart murmur beyond a typical flow murmur.&#xD;
&#xD;
          -  Chronic pain syndromes like headaches or back pain requiring use (more than once per&#xD;
             week) of over-the-counter medications like Tylenol or NSAIDs.&#xD;
&#xD;
          -  Elevated iron stores, evidence of chronic hemolysis such as abnormal blood smear,&#xD;
             elevated transferrin or transferrin saturation &gt;50% (Iron overload predisposes to&#xD;
             listeriosis and asymptomatic elevated iron level may indicate early iron overload&#xD;
             state, i.e. hemochromatosis).&#xD;
&#xD;
          -  Any evidence of immunosuppressive illness (e.g. HIV or malignancy) or seropositive for&#xD;
             HIV or hepatitis B (sAg positive) or C, or history of frequent infections especially&#xD;
             sino-pulmonary, skin or soft tissue or GI infections. Hepatitis B serologies&#xD;
             consistent with vaccination or resolved prior infection (surface antibody positive and&#xD;
             surface antigen negative) is not a reason for exclusion.&#xD;
&#xD;
          -  Subjects who live with immunosuppressed individuals, children under 4 years of age, or&#xD;
             people with chronic skin disorders in the household are excluded.&#xD;
&#xD;
          -  Alcohol or substance abuse (immunosuppressive affects of alcohol and altered immune&#xD;
             responses) by history. Occasional recreational use of marijuana, or social alcohol use&#xD;
             are not exclusion criteria. Drug testing is not performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth L Hohmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <last_update_submitted>September 30, 2015</last_update_submitted>
  <last_update_submitted_qc>September 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth L. Hohmann, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

